Skip to main content

Catalyst Calendar

Scope

Thu, Sep 24, 2026

1 updates
HCWB
8:25 AM

HCW Biologics Announces Pricing of $1.5 Million Private Placement

MIRAMAR, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today

hcwbiologics.com

Tue, Sep 8, 2026

1 updates

Wed, Sep 2, 2026

1 updates
HCWB
9:00 AM

HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment

HCW9302 is a best-in-class IL-2-based immunotherapeutic for treatment of autoimmune diseases through expanding and activating regulatory T cells Patent allowance received for use of HCW9302 as treatment for alopecia areata Phase 1 dose-escalating clinical study evaluating HCW9302 as monotherapy in

Interim Data • Phase 1Interim data Tue, Mar 31, 2026hcwbiologics.com

Tue, Aug 25, 2026

1 updates

Fri, Aug 14, 2026

1 updates

Wed, Jul 29, 2026

1 updates

Thu, Jul 23, 2026

1 updates